James Hamilton serves as the Chief of Discovery and Translational Medicine at Arrowhead Pharmaceuticals Inc., a position that places him at the forefront of the company's efforts to develop innovative therapies. With a robust background in molecular biology and pharmacology, Hamilton has spent over two decades in the biopharmaceutical industry. Prior to joining Arrowhead, he held significant roles at several leading biotech firms, where he was instrumental in advancing drug discovery programs from the bench to clinical trials. His expertise in translating scientific discoveries into viable medical treatments has made him a valuable asset to Arrowhead's mission of targeting intractable diseases with RNA-based therapies. At Arrowhead Pharmaceuticals, Hamilton oversees a dynamic team responsible for the discovery and early development of new therapeutic candidates. His leadership has been pivotal in driving the company's pipeline forward, particularly in the areas of cardiovascular, metabolic, and liver diseases. Under his guidance, Arrowhead has successfully advanced several RNAi-based therapeutics into clinical development, showcasing his ability to navigate the complex landscape of drug development. Hamilton's strategic vision and commitment to scientific excellence have not only bolstered Arrowhead's position in the industry but have also contributed to the broader field of translational medicine. In addition to his role at Arrowhead, Hamilton is an active member of the scientific community, frequently contributing to peer-reviewed journals and speaking at international conferences. His work has been recognized with numerous awards and honors, reflecting his significant contributions to the field. Hamilton's dedication to advancing medical science and improving patient outcomes continues to drive his work, making him a respected leader and innovator in the biopharmaceutical sector.